Mankind Pharma: Inside the Chronic Growth Segment and Premium Valuations
India’s fifth-largest drugmaker is thriving in diabetes and cardiac care while waiting for its infection-treatment business to recover Mankind Pharma […]
India’s fifth-largest drugmaker is thriving in diabetes and cardiac care while waiting for its infection-treatment business to recover Mankind Pharma […]
India’s Jockey licensee is managing margins brilliantly while volume growth stalls. Page Industries delivered a technically clean third quarter, beating
The financial conglomerate’s long-suffering insurance arms are rebounding. But is that enough to justify a valuation that’s relied heavily on
The central bank holds repo rate steady at 5.25% – here’s what it means for your fixed deposits, mutual funds,
India’s state-owned iron ore miner is digging itself into a profitability hole. Higher output can’t compensate for soaring costs and
India’s second-largest paint maker is chasing market share at the expense of profitability, why that may not paint a good
India’s hotel operator is mastering the art of rate increases while learning the hard way that filling new inventory takes
Morgan Stanley’s harsh downgrade signals a structural shift threatening the state aerospace champion’s monopoly India’s state-owned aerospace champion may be
India’s consumer lending giant is front-loading provisions in a bet that pessimism today beats nasty surprises tomorrow. Investors aren’t convinced—yet.
India’s largest private port operator is shifting gears from mere cargo handler to end-to-end supply chain powerhouse—and investors are taking